Background and Rationale Carbapenem-resistant Enterobacterales (CRE) pose a growing threat in healthcare settings due to limited treatment options and high mortality. Colistin, often used as a backbone of therapy, is frequently combined with carbapenems like meropenem in attempts to broaden antimicrobial activity and suppress resistance. The AIDA randomized trial investigates whether colistin monotherapy or a…